Wadhwa Karan, Patruno Giulio, Patterson Andrew, Barrett Tristan, Dalia Chandni, Koo Brendan C, Gallagher Ferdia A, Serrao Eva, Warren Anne, Gnanapragasam Vincent, Shah Nimish, Doble Andrew, Kastner Christof
CamPARI Clinic, Addenbrookes Hospital and University of Cambridge, Cambridge, UK -
Department of Urology, Addenbrooke's Hospital, Cambridge, UK -
Minerva Urol Nefrol. 2017 Feb;69(1):85-92. doi: 10.23736/S0393-2249.16.02759-4. Epub 2016 Sep 29.
To assess if transperineal prostate (TP) biopsy affects th e outcome of robotic-assisted laparoscopic prostatectomy (RALP), with particular reference to perioperative complications, oncological results and functional outcomes in the early postoperative setting.
We identified 61 men who had undergone RALP after TP biopsies, from June 2012 to June 2014 and a control group of 120 men who had undergone RALP after conventional TRUS biopsy in the same period. Data was compared from the pre-operative biopsy, peri- and postoperative period, procedural outcomes including histological, oncological and functional outcomes between the groups.
The groups had comparable demographics, with matched median ages and PSA levels. There was a higher incidence of Gleason 6 disease detected in the TRUS group (P=0.01). Mean operative time (146 minutes TRUS vs. 158 minutes TP, P=0.133), blood loss (250 mL TRUS vs. 288 mL TP, P=0.462) and intraoperative complications were not significantly different between groups. Median length of stay (1 day) and median catheter duration (7 days) were identical in both cohorts. PSA failure rate at 6 months was similar (11.7% TRUS vs. 9.8% TP, P=0.904). There were no differences in functional outcomes (potency or continence) between groups at 6 month s follow-up.
RALP is safe after TP biopsy with no adverse impact on oncological or short-term functional outcomes.
